(RTTNews) - Revolution Medicines (RVMD) on Thursday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for RASONQUE (daraxonrasib) to treat adults with metastatic pancreatic adenocarcinoma who have re
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.